Needham analyst Gil Blum maintained a Buy rating on Autolus Therapeutics today and set a price target of $10.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Gil Blum has given his Buy rating due to a combination of factors that indicate potential growth and success for Autolus Therapeutics. The company’s sales for the third quarter were consistent with expectations, and there is an anticipation of increased sales in the fourth quarter. This optimism is supported by the company’s achievement in activating more ATCs, which is a positive indicator of future performance.
Additionally, Autolus’s manufacturing process has shown impressive results with a high success rate, and there are expectations for cost efficiencies as patient volumes increase. The upcoming presentations at the ASH meeting, including the ROCCA presentation and data updates for obe-cel and SLE, are expected to highlight the company’s advancements and potential in the therapeutic space. These factors collectively contribute to the Buy rating, reflecting confidence in the company’s strategic direction and future prospects.
Blum covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Autolus Therapeutics, and Recursion Pharmaceuticals. According to TipRanks, Blum has an average return of 4.7% and a 39.76% success rate on recommended stocks.